title: Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
authors.affiliation: Tacoma Family Medicine Residency Program, University of Washington, Tacoma, USA. jguirgui@u.washington.edu
authors.forename: Janelle
authors.initials: J
authors.lastname: Guirguis-Blake
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000799:Angioedema / Q000139:chemically induced; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D003371:Cough / Q000139:chemically induced; D004244:Dizziness / Q000139:chemically induced; D004359:Drug Therapy, Combination; D006261:Headache / Q000139:chemically induced; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000401:mortality; D009204:Myocardial Revascularization; D010359:Patient Readmission; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000517:prevention & control; D000077333:Telmisartan
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D000077333:Telmisartan